Sanger Institute Spin-Out Microbiotica To Evaluate Bacterial Mixes
The UK Wellcome Trust Sanger Institute’s latest spin-out has received start-up funding to exploit more than six years of gut bacterial genome sequencing in order to develop novel bacteria-based therapies for a range of diseases.
You may also be interested in...
Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.
Cambridge Innovation Capital, an investment firm focused on the University of Cambridge and the "Cambridge Cluster", has raised £75m for its healthcare fund in order to pursue new opportunities and expand its staff – a move highlighted as promising for the life sciences sector in the aftermath of Brexit.
Seventure Partners' new VC fund focused on the microbiome revolution has €160m to invest in the areas of health and nutrition.